FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond.

The worldwide epidemics of obesity, hypertriglyceridemia, dyslipidemia, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD) / metabolic dysfunction-associated steatohepatitis (MASH) represents a major economic burden on healthcare systems. At-risk MASH patients, defined as MASH with moderate or significant fibrosis are at higher risk of comorbidity / mortality with a significant risk of cardiovascular diseases and/or major adverse liver outcomes. Despite a high unmet medical need, there is no approved therapy to date. Several drug candidates have reached the phase 3 development stage and could lead to several potential conditional drug approvals in the coming years. Within the armamentarium of future treatment options, FGF21 analogs exhibit an interesting positioning thanks to their pleiotropic effects in addition to their significant effect on both MASH resolution and fibrosis improvement. In this review, we summarize preclinical and clinical data from FGF21 analogs for MASH and explore additional potential therapeutic indications.

• Publication year

  2024

• Venue

  Journal of Hepatology

• Publication date

  2024-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jhep.2024.04.034PMID 38710230
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.

  2024cited by this paper
• Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.

  2023cited by this paper
• Renoprotective effects of genetically proxied fibroblast growth factor 21: Mendelian randomization, proteome-wide and metabolome-wide association study.

  2023cited by this paper
• Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.

  2023cited by this paper
• FGF21 Counteracts Alcohol Intoxication by Activating the Noradrenergic Nervous System

  2023cited by this paper
• Role of hepatic deiodinases in thyroid hormone homeostasis and liver metabolism, inflammation, and fibrosis

  2023cited by this paper
• Investigation of FGF21 mRNA levels and relative mitochondrial DNA copy number levels and their relation in nonalcoholic fatty liver disease: a case-control study

  2023cited by this paper
• Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets

  2023cited by this paper
• Noncompetitive immunoassay optimized for pharmacokinetic assessments of biologically active efruxifermin.

  2023cited by this paper
• The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers

  2023cited by this paper
• Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study.

  2023cited by this paper
• Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study.

  2023cited by this paper
• Genome-wide association and Mendelian randomization study of fibroblast growth factor 21 reveals causal associations with hyperlipidemia and possibly NASH.

  2022cited by this paper
• A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis

  2022cited by this paper
• Many roads lead to Rome: The FGF4–AMP‐activated protein kinase–Caspase 6 signal axis in NAFLD and NASH

  2022cited by this paper
• American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).

  2022cited by this paper
• Reduced triglycerides and LDL cholesterol from once-weekly administration of the well-tolerated novel FGF21 analogue 0499

  2022cited by this paper
• Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.

  2022cited by this paper
• LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in obese adults with modest hypertriglyceridemia.

  2021cited by this paper
• Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

  2021cited by this paper
• The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation

  2021cited by this paper
• Adiponectin Alleviates Diet-Induced Inflammation in the Liver by Suppressing MCP-1 Expression and Macrophage Infiltration

  2021cited by this paper
• The Ameliorate Effects of Nerolidol on Thioacetamide-induced Oxidative Damage in Heart and Kidney Tissue

  2021cited by this paper
• Fibroblast growth factor 21 attenuates iron overload-induced liver injury and fibrosis by inhibiting ferroptosis

  2021cited by this paper
• High-Level Serum Fibroblast Growth Factor 21 Concentration Is Closely Associated With an Increased Risk of Cardiovascular Diseases: A Systematic Review and Meta-Analysis

  2021cited by this paper
• Sarcopenia in cirrhosis: A practical overview.

  2020cited by this paper
• Fructose metabolism as a common evolutionary pathway of survival associated with climate change, food shortage and droughts

  2020cited by this paper
• FGF19 and FGF21: In NASH we trust

  2020cited by this paper
• A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

  2020cited by this paper
• AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients

  2020cited by this paper
• Diagnostic value of serum biomarkers FGF21 and GDF15 compared to muscle sample in mitochondrial disease

  2020cited by this paper
• The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic

  2020cited by this paper
• FGF21 Signals to Glutamatergic Neurons in the Ventromedial Hypothalamus to Suppress Carbohydrate Intake.

  2020cited by this paper
• Fibroblast Growth Factor–21 ameliorates hepatic encephalopathy by activating the STAT3-SOCS3 pathway to inhibit activated hepatic stellate cells

  2020cited by this paper
• Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases

  2020cited by this paper
• Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

  2020cited by this paper
• A single combination gene therapy treats multiple age-related diseases

  2019cited by this paper
• Fibroblast Growth Factor 21 Drives Dynamics of Local and Systemic Stress Responses in Mitochondrial Myopathy with mtDNA Deletions.

  2019cited by this paper
• Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes

  2019cited by this paper
• The FGF metabolic axis

  2019cited by this paper
• FGF19 Analog as a Surgical Factor Mimetic That Contributes to Metabolic Effects Beyond Glucose Homeostasis

  2019cited by this paper
• Autophagic control of cardiac steatosis through FGF21 in obesity-associated cardiomyopathy.

  2018cited by this paper
• Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling

  2018cited by this paper
• Adiponectin Signaling Pathways in Liver Diseases

  2018cited by this paper
• Defining “FGF21 Resistance” during obesity: Controversy, criteria and unresolved questions

  2018cited by this paper
• FGF21 attenuates pulmonary fibrogenesis through ameliorating oxidative stress in vivo and in vitro.

  2018cited by this paper
• NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

  2018cited by this paper
• Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.

  2018cited by this paper
• Bone turnover: Biology and assessment tools.

  2018cited by this paper
• LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate—G-protein couple receptor 91 (GPR91) pathway in mice

  2018cited by this paper
• FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest

  2018cited by this paper
• FGF21 Is an Exocrine Pancreas Secretagogue.

  2017cited by this paper
• FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms.

  2017cited by this paper
• Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non‐human primates

  2017cited by this paper
• A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward &bgr;-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys

  2017cited by this paper
• Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis

  2017cited by this paper
• Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury

  2017cited by this paper
• Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease

  2017cited by this paper
• FGF21 Is a Sugar-Induced Hormone Associated with Sweet Intake and Preference in Humans.

  2017cited by this paper
• Diverse Changes of Circulating Fibroblast Growth Factor 21 Levels in Hepatitis B Virus-Related Diseases

  2017cited by this paper
• FGF21 deficiency is associated with childhood obesity, insulin resistance and hypoadiponectinaemia: The BCAMS Study.

  2017cited by this paper
• Fasting-induced hormonal regulation of lysosomal function

  2017cited by this paper
• FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists

  2017cited by this paper
• KLB, encoding β‐Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism

  2017cited by this paper
• Alterations in 3-Hydroxyisobutyrate and FGF21 Metabolism Are Associated With Protein Ingestion–Induced Insulin Resistance

  2017cited by this paper
• Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway.

  2016cited by this paper
• FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues.

  2016cited by this paper
• Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways.

  2016cited by this paper
• Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21*

  2016cited by this paper
• Adiponectin: a versatile player of innate immunity.

  2016cited by this paper
• How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes

  2016cited by this paper
• A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects.

  2016cited by this paper
• FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders

  2016cited by this paper
• Understanding the Physiology of FGF21.

  2016cited by this paper
• FGF21 Mediates Endocrine Control of Simple Sugar Intake and Sweet Taste Preference by the Liver.

  2016cited by this paper
• Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus

  2016cited by this paper
• Pharmacokinetics (PK), Pharmacodynamics (PD) and Integrated PK/PD Modeling of a Novel Long Acting FGF21 Clinical Candidate PF-05231023 in Diet-Induced Obese and Leptin-Deficient Obese Mice

  2015cited by this paper
• The Fibroblast Growth Factor signaling pathway

  2015cited by this paper
• Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet.

  2015cited by this paper
• Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders

  2015cited by this paper
• Serum Level of Fibroblast Growth Factor 21 Is Independently Associated with Acute Myocardial Infarction

  2015cited by this paper
• Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis.

  2015cited by this paper
• Resetting the transcription factor network reverses terminal chronic hepatic failure.

  2015cited by this paper
• Fructose ingestion acutely stimulates circulating FGF21 levels in humans

  2014cited by this paper
• Fibroblast growth factor 21 protects against acetaminophen‐induced hepatotoxicity by potentiating peroxisome proliferator‐activated receptor coactivator protein‐1α‐mediated antioxidant capacity in mice

  2014cited by this paper
• FGF21 is an endocrine signal of protein restriction.

  2014cited by this paper
• Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.

  2014cited by this paper
• Medication-induced osteoporosis: screening and treatment strategies

  2014cited by this paper
• Fibroblast growth factor-21 enhances mitochondrial functions and increases the activity of PGC-1α in human dopaminergic neurons via Sirtuin-1

  2014cited by this paper
• Adiponectin protects against acetaminophen-induced mitochondrial dysfunction and acute liver injury by promoting autophagy in mice.

  2014cited by this paper
• Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients

  2014cited by this paper
• Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.

  2014cited by this paper
• Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice.

  2013cited by this paper
• Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319

  2013cited by this paper
• Fibroblast growth factor 21 protects against cardiac hypertrophy in mice

  2013cited by this paper
• Activation of Autophagy by Globular Adiponectin Attenuates Ethanol‐induced Apoptosis in HepG2 Cells

  2013cited by this paper
• The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.

  2013cited by this paper
• FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents

  2012cited by this paper
• Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine

  2012cited by this paper
• Characterization of a FGF19 Variant with Altered Receptor Specificity Revealed a Central Role for FGFR1c in the Regulation of Glucose Metabolism

  2012cited by this paper

• Decoding the mechanistic basis of liver-muscle communication in health and disease.

  2026cites this paper
• Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart-liver co-management.

  2026cites this paper
• Prise en charge clinique et thérapeutique des hépatopathies stéatosiques associées à une dysfonction métabolique (MASLD)

  2026cites this paper
• High-protein diets and metabolic dysfunction-associated steatotic liver disease: A double-edged sword in liver health

  2026cites this paper
• Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis

  2026cites this paper
• Retatrutide in type 2 diabetes mellitus and obesity: an overview.

  2026cites this paper
• Serum soluble ASGR1 concentration is elevated in patients with metabolic dysfunction-associated steatotic liver disease and is associated with adiponectin

  2026cites this paper
• Feasibility of remnant cholesterol as a therapeutic target for atherosclerotic cardio-vascular disease.

  2026cites this paper
• Genetic evidence that FGF21 signaling reduces problematic alcohol use and alcohol-related liver disease.

  2026cites this paper
• HFpEF and MASLD: converging mechanisms and clinical implications.

  2026cites this paper
• MetALD: A narrative review of the clinical and molecular landscape of reclassifying steatotic liver disease.

  2026cites this paper
• Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution.

  2026cites this paper
• CircZBTB46 alleviates metabolic dysfunction–associated steatotic liver disease by targeting miRNA-326/FGF1 axis

  2026cites this paper
• Synergistic therapeutic strategies for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: molecular insights and clinical advances

  2026cites this paper
• Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis.

  2026cites this paper
• Liver–pancreas communication in disease and drug development

  2026cites this paper
• Basal metabolic rate as a protective factor against osteoporosis: a multi-cohort longitudinal study from three international aging databases

  2026cites this paper
• Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease

  2025cites this paper
• Secreted proteins in treating metabolic dysfunction-associated steatotic liver disease: from bench towards bedside

  2025cites this paper
• Intestinal failure-associated steatosis and fibroblast growth factor 21 plasma levels among adult chronic intestinal failure patients.

  2025cites this paper
• Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.

  2025cites this paper
• Target Populations for Novel Triglyceride-Lowering Therapies.

  2025cites this paper
• Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD

  2025cites this paper
• FGF21 reverses MASH through coordinated actions on the CNS and liver.

  2025cites this paper
• Decoding the Liver-Heart Axis in Cardiometabolic Diseases

  2025cites this paper
• Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease

  2025cites this paper
• Gene therapy strategies for aging intervention

  2025cites this paper
• Molecular insights into herbal medicines for the treatment of metabolic associated Steatohepatitis

  2025cites this paper
• The Predictive Role of FGF21 in Acute Liver Injury Caused by Bacterial Infectious Diseases in Critical Care: A Retrospective Cohort Study

  2025cites this paper
• Circulating FGF21 and Ketone Bodies Modify the Risk of MASLD and Mortality: Insights from the PREVEND Cohort Study

  2025cites this paper
• Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective

  2025influential citation
• Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms.

  2025cites this paper
• Immunopathogenic mechanisms and immunoregulatory therapies in MASLD

  2025cites this paper
• Analytical and Clinical Validation of a Plasma Fibroblast Growth Factor 21 ELISA Kit Using an Automated Platform in Steatotic Liver Disease

  2025cites this paper
• Intercellular communication between hepatic stellate cells and myofibroblasts mediated by osteopontin and FGF18 promotes liver fibrosis

  2025cites this paper
• Bioinspired Prolactin Pulse Release from Responsive Microneedles for Inhibiting Fatty Liver Formation

  2025cites this paper
• Extrahepatic manifestations of metabolic dysfunction-associated steatotic liver disease: An updated clinical overview

  2025cites this paper
• Dysregulation of the FGF21–Adiponectin Axis in a Large Cohort of Patients with Severe Obesity and Liver Disease

  2025cites this paper
• The Cardiohepatic Axis in Metabolic Disease

  2025cites this paper
• A newly revealed signaling pathway may explain the conundrum of how FGF21 simultaneously increases insulin sensitivity and autophagy.

  2025cites this paper
• Effects and Safety of FGF21 Analogs on Glycemic Parameters, Lipid Profiles, and Adiponectin in Overweight and Obese Adults: A Meta-Analysis of Randomized Controlled Trials

  2025cites this paper
• Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis

  2025cites this paper
• Adipokine and Hepatokines in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current and Developing Trends

  2025cites this paper
• Halting Hypercaloric Feeding in Liver Chimeric Mice Rapidly Resolves Human Hepatocyte Steatosis

  2025cites this paper
• Neuro-endocrine-immune regulation of metabolic homeostasis.

  2025cites this paper
• Future potential therapeutics to treat MASH.

  2025cites this paper
• Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.

  2025cites this paper
• Safety Choice Drivers of the Coming Treatment Options for Non‐Cirrhotic Metabolic Steatohepatitis

  2025cites this paper
• Exploring the potential role of fibroblast growth factors in alleviating hepatic ischemia-reperfusion injury: From in vitro insights to clinical investigations.

  2025cites this paper
• Research progress on the role of FGF21 in insulin resistance

  2025cites this paper
• Potential missed opportunities to improve long-term liver allograft health.

  2025cites this paper
• Fibroblast Growth Factor 21 Agonists for the Treatment of Patients With Metabolic Dysfunction-Associated Steatohepatitis.

  2025cites this paper
• Congresverslag

  2025cites this paper
• The physiology of MASLD: molecular pathways between liver and adipose tissues

  2025influential citation
• Liver immunology: Biological role and clinical significance

  2025cites this paper
• Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)

  2025cites this paper
• Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction

  2025cites this paper
• FGF21 Alleviates Diabetic Vasculopathy with NF-κB Suppression and Fibrinolytic Activation.

  2025cites this paper
• Metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factors, and cardiovascular disease.

  2025cites this paper
• HSD17B13 Couples Hepatocyte Lipid Metabolism to Stellate Cell Activation via TGFb-1 Signaling

  2025cites this paper
• Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis

  2025cites this paper
• Metabolic and Alcohol-Associated: Diagnosis and Management.

  2025cites this paper
• Fibroblast growth factor receptor: Bidirectional regulatory role and therapeutic potential in cardiovascular disease.

  2025cites this paper
• Advances of pharmacological therapies in lipodystrophy syndromes: current evidence and future directions

  2025cites this paper
• Progressive fibrosis in human MASLD is associated with spatially linked transcriptomic signatures of metabolic reprogramming and senescence

  2025cites this paper
• Lessons from recent clinical trials for the prevention of acute pancreatitis in chylomicronemia syndromes.

  2025cites this paper
• Lipid management for primary and secondary stroke prevention consensus paper of the International Lipid Expert Panel (ILEP).

  2025cites this paper
• Oral gene delivery platform based on glycol chitosan-PEG-lactoferrin conjugate.

  2025cites this paper
• Rab2A modulates liver fibroblast growth factor 21 (FGF21) expression and systemic metabolism via apolipoprotein B–CREBH signaling

  2025cites this paper
• Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis.

  2025cites this paper
• Targeting Mitochondrial Dysfunction for the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease

  2025cites this paper
• New molecules for treating Metabolic-associated dysfunction steatotic liver disease (MASLD).

  2025cites this paper
• MASLD and MASH increase fracture risk in humans and mice by arresting new bone formation

  2025cites this paper
• FGF21 inhibits invasion and metastasis via IL-17A-Notch in pancreatic ductal adenocarcinoma

  2025cites this paper
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Long‐Acting FGF21 Analog Zalfermin

  2025cites this paper
• Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends

  2025cites this paper
• FGF21 attenuates traumatic brain injury-induced ferroptosis via activation of the Nrf2/GPX4 pathway.

  2025cites this paper
• Integrating Network Pharmacology, Molecular Docking, and Experimental Validation: Andrographolide Attenuates Acute Liver Injury via the NLRP3/Caspase-1/GSDMD-Mediated Pyroptosis Pathway

  2025cites this paper
• Drug treatment of MASH from none to (too) many options?

  2025cites this paper
• FGF21 and the brain-liver axis: Harnessing sympathetic pathways in MASH.

  2025cites this paper
• Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics

  2025cites this paper
• New drug therapies for metabolic dysfunction-associated steatohepatitis

  2025cites this paper
• Assessment of skeletal muscle alterations and circulating myokines in metabolic dysfunction-associated steatotic liver disease: A cross-sectional study

  2025cites this paper
• Therapeutic Strategies for MASH: An Update on Drug Candidates Under Investigation in Late-Phase Clinical Trials

  2025influential citation
• FGF21 Analogues in Patients With Metabolic Diseases: Systematic Review and Meta‐Analysis of Randomised Controlled Trials

  2025cites this paper
• Reactive Dicarbonyl Scavenging with 2-Hydroxybenzylamine Improves MASH

  2025cites this paper
• Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes

  2025cites this paper
• Pharmacological treatment options for metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review

  2025cites this paper
• Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment

  2025cites this paper
• A comparative genomic study across 396 liver biopsies provides deep insight into FGF21 mode of action as a therapeutic agent in metabolic dysfunction‐associated steatotic liver disease

  2025cites this paper
• A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control

  2025cites this paper
• Subtypes of MASLD confer distinct clinical trajectories.

  2025cites this paper
• Fibroblast growth factor receptor signaling in metabolic dysfunction-associated fatty liver disease: Pathogenesis and therapeutic targets.

  2025cites this paper
• Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment

  2025influential citation
• Mitochondrial dysfunction characterises the multigenerational effects of maternal obesity on MASLD

  2025cites this paper
• Inflammation in MASLD progression and cancer

  2025cites this paper
• Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis.

  2024cites this paper
• Role of signaling pathways in age-related orthopedic diseases: focus on the fibroblast growth factor family

  2024cites this paper
• A Moderate Intake of Beer Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a High-Fat Diet (HFD)-Induced Mouse Model

  2024cites this paper